Seema Naik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Seema Naik has a total of 315 co-authors. Here are the top co-authors by number of shared publications:
- Narendranath Epperla
Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, USA
5 shared publications - Shin Mineishi
Blood and Marrow Transplant Program, Division of Hematology and Oncology, Penn State Cancer Institute, Hershey, PA 17033, USA
5 shared publications - David F. Claxton
Division of Hematology and Oncology, Department of Medicine, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA
4 shared publications - Hong Zheng
Penn State Cancer Institute, Penn State University College of Medicine, Hershey, USA
4 shared publications - Adam Zayac
Division of Hematology/Oncology, Brown University, Providence, RI
3 shared publications - Andrzej Olszewski
Department of Medicine, Brown University, Providence, RI
3 shared publications
Latest Publications
- Open Access
- 12 June 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (9) , 2177-2189
A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma
Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R‐Pola) in patients with relapsed/refractory (R/R) large B‐cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun‐Pola), with > 2 years of follow‐up. Patients with R/R LBCL and ≥ 1 prior line of therapy were randomized to receive Mosun‐Pola or R‐Pola. Mosunetuzumab was administered subcutaneously with Cycle (C) 1 step‐up dosing (5/45/45 mg) then 45 mg on C2 Day (D) 1–C8D1 (21‐day cycles). Polatuzumab vedotin (1.8 mg/kg) was given intravenously (IV) on D1 of C1–6. Rituximab IV (375 mg/m 2 ) was given on D1 of C1–8. Primary endpoint was best objective response rate (ORR). As of November 15, 2024, 80 patients had been enrolled (Mosun‐Pola, n = 40; R‐Pola, n = 40). Best ORR was 77.5% (95% confidence interval [CI] 61.6–89.2) for Mosun‐Pola and 50.0% (95% CI: 33.8–66.2) for R‐Pola; complete response (CR) rates were 55.0% (95% CI: 38.5–70.7) and 35.0% (95% CI: 20.6–51.7), respectively. Median progression‐free survival was 25.4 months for Mosun‐Pola and 6.4 months for R‐Pola (hazard ratio [HR] 0.47); median overall survival was not reached and 25.5 months (HR: 0.78), respectively. Cytokine release syndrome occurred in 12.5% of Mosun‐Pola‐treated patients (all Grade 1/2). Fixed‐duration Mosun‐Pola demonstrated benefit across all efficacy endpoints compared with R‐Pola in patients with R/R LBCL. These findings are consistent with the observed benefit of Mosun‐Pola for patients with R/R LBCL in the global Phase III SUNMO study (NCT05171647). Trial Registration: Clinicaltrials.gov number: NCT03671018
- 12 June 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (9) , 2177-2189
Open AccessA Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma
Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R‐Pola) in patients with relapsed/refractory (R/R) large B‐cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun‐Pola), with > 2 years of follow‐up. Patients with R/R LBCL and ≥ 1 prior line of therapy were randomized to receive Mosun‐Pola or R‐Pola. Mosunetuzumab was administered subcutaneously with Cycle (C) 1 step‐up dosing (5/45/45 mg) then 45 mg on C2 Day (D) 1–C8D1 (21‐day cycles). Polatuzumab vedotin (1.8 mg/kg) was given intravenously (IV) on D1 of C1–6. Rituximab IV (375 mg/m 2 ) was given on D1 of C1–8. Primary endpoint was best objective response rate (ORR). As of November 15, 2024, 80 patients had been enrolled (Mosun‐Pola, n = 40; R‐Pola, n = 40). Best ORR was 77.5% (95% confidence interval [CI] 61.6–89.2) for Mosun‐Pola and 50.0% (95% CI: 33.8–66.2) for R‐Pola; complete response (CR) rates were 55.0% (95% CI: 38.5–70.7) and 35.0% (95% CI: 20.6–51.7), respectively. Median progression‐free survival was 25.4 months for Mosun‐Pola and 6.4 months for R‐Pola (hazard ratio [HR] 0.47); median overall survival was not reached and 25.5 months (HR: 0.78), respectively. Cytokine release syndrome occurred in 12.5% of Mosun‐Pola‐treated patients (all Grade 1/2). Fixed‐duration Mosun‐Pola demonstrated benefit across all efficacy endpoints compared with R‐Pola in patients with R/R LBCL. These findings are consistent with the observed benefit of Mosun‐Pola for patients with R/R LBCL in the global Phase III SUNMO study (NCT05171647). Trial Registration: Clinicaltrials.gov number: NCT03671018
- Open Access
- 2 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (11) , 5026
Molecular Insights and Novel Therapies for Lymphoproliferative Disorders
Hematological malignancies encompass a broad spectrum of relatively rare cancers with diverse biological and clinical characteristics that are capable of affecting individuals across all age groups, though certain subtypes show a predilection for specific age ranges. Advances in next-generation sequencing have greatly enhanced our understanding of the molecular and genetic basis of these diseases, while epigenetic, transcriptional, and proteomic analyses have further clarified their pathogenesis. These developments have shaped the classification and treatment of lymphoma. Updated classification frameworks which include the identification of clinically relevant molecular targets have opened the door to a number of targeted agents, each designed to exploit specific vulnerabilities within malignant cells, while stem cell transplantation continues to offer curative potential for eligible patients, with improving safety profiles over time. CAR-T-cell therapy has been extended to multiple blood cancer indications, achieving lasting remissions in patients with previously exhausted treatment options. Bispecific antibodies have further broadened the immunotherapy landscape by redirecting the body’s own T cells against tumor cells, offering a readily available alternative that overcomes many of the practical limitations associated with CAR-T-cell production. The ability to combine these strategies has fundamentally changed what is achievable in blood cancer treatment, with long-term remission now a realistic goal for many patients. This review seeks to outline the core molecular mechanisms underlying lymphoma and leukemia, evaluate currently approved treatment options, discuss significant ongoing clinical trials with practice-changing potential, and explore the prospect of chemotherapy-free approaches in carefully selected patient groups.
- 2 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (11) , 5026
Open AccessMolecular Insights and Novel Therapies for Lymphoproliferative Disorders
Hematological malignancies encompass a broad spectrum of relatively rare cancers with diverse biological and clinical characteristics that are capable of affecting individuals across all age groups, though certain subtypes show a predilection for specific age ranges. Advances in next-generation sequencing have greatly enhanced our understanding of the molecular and genetic basis of these diseases, while epigenetic, transcriptional, and proteomic analyses have further clarified their pathogenesis. These developments have shaped the classification and treatment of lymphoma. Updated classification frameworks which include the identification of clinically relevant molecular targets have opened the door to a number of targeted agents, each designed to exploit specific vulnerabilities within malignant cells, while stem cell transplantation continues to offer curative potential for eligible patients, with improving safety profiles over time. CAR-T-cell therapy has been extended to multiple blood cancer indications, achieving lasting remissions in patients with previously exhausted treatment options. Bispecific antibodies have further broadened the immunotherapy landscape by redirecting the body’s own T cells against tumor cells, offering a readily available alternative that overcomes many of the practical limitations associated with CAR-T-cell production. The ability to combine these strategies has fundamentally changed what is achievable in blood cancer treatment, with long-term remission now a realistic goal for many patients. This review seeks to outline the core molecular mechanisms underlying lymphoma and leukemia, evaluate currently approved treatment options, discuss significant ongoing clinical trials with practice-changing potential, and explore the prospect of chemotherapy-free approaches in carefully selected patient groups.
- Top Cited PapersOpen Access
- 21 April 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (6) , 682-692
Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study
Patients with relapsed/refractory mantle cell lymphoma (MCL), especially those progressing after Bruton tyrosine kinase (BTK) inhibitor and/or chimeric antigen receptor (CAR) T-cell therapy and those with high-risk features, have poor outcomes. The bispecific antibody, mosunetuzumab, combined with the antibody-drug-conjugate (ADC), polatuzumab vedotin (Mosun-Pola), targets CD20 and CD79b via independent cell-killing mechanisms. In this multicenter phase 2 study, patients with MCL who had received ≥2 prior lines of therapy, including a BTK inhibitor, were enrolled. Patients received outpatient fixed-duration mosunetuzumab subcutaneously (17 cycles), with Cycle 1 step-up dosing to mitigate cytokine release syndrome, and polatuzumab vedotin (1.8 mg/kg intravenously) for 6 cycles. The primary endpoint was centrally assessed best objective response rate. Forty-two patients with a median of 3 prior therapies were enrolled; 26% had prior CAR T-cell therapy. A number of patients had MCL with high-risk features (Ki-67 ≥50%, 67%; blastoid/pleomorphic morphology, 38%; TP53 aberration, 48%). Objective response occurred in 88.1% of evaluable patients (95% CI, 74.4-96.0) and complete response in 78.6% (95% CI, 63.2-89.7). With a median follow-up of 15.9 months, median progression-free survival was 18.6 months (95% CI, 13.9-not estimable). Consistent efficacy was observed in high-risk subgroups. Cytokine release syndrome occurred in 42.9% of patients and was limited to Grade 1-2 events. Mosun-Pola achieved high complete remission rates while maintaining a manageable safety profile in patients with relapsed/refractory MCL exhibiting high-risk features. This is the first bispecific-ADC combination therapy study in MCL. (Funded by F. Hoffmann-La Roche Ltd; ClinicalTrials.gov, NCT03671018)
- 21 April 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (6) , 682-692
Top Cited PapersOpen AccessMosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study
Patients with relapsed/refractory mantle cell lymphoma (MCL), especially those progressing after Bruton tyrosine kinase (BTK) inhibitor and/or chimeric antigen receptor (CAR) T-cell therapy and those with high-risk features, have poor outcomes. The bispecific antibody, mosunetuzumab, combined with the antibody-drug-conjugate (ADC), polatuzumab vedotin (Mosun-Pola), targets CD20 and CD79b via independent cell-killing mechanisms. In this multicenter phase 2 study, patients with MCL who had received ≥2 prior lines of therapy, including a BTK inhibitor, were enrolled. Patients received outpatient fixed-duration mosunetuzumab subcutaneously (17 cycles), with Cycle 1 step-up dosing to mitigate cytokine release syndrome, and polatuzumab vedotin (1.8 mg/kg intravenously) for 6 cycles. The primary endpoint was centrally assessed best objective response rate. Forty-two patients with a median of 3 prior therapies were enrolled; 26% had prior CAR T-cell therapy. A number of patients had MCL with high-risk features (Ki-67 ≥50%, 67%; blastoid/pleomorphic morphology, 38%; TP53 aberration, 48%). Objective response occurred in 88.1% of evaluable patients (95% CI, 74.4-96.0) and complete response in 78.6% (95% CI, 63.2-89.7). With a median follow-up of 15.9 months, median progression-free survival was 18.6 months (95% CI, 13.9-not estimable). Consistent efficacy was observed in high-risk subgroups. Cytokine release syndrome occurred in 42.9% of patients and was limited to Grade 1-2 events. Mosun-Pola achieved high complete remission rates while maintaining a manageable safety profile in patients with relapsed/refractory MCL exhibiting high-risk features. This is the first bispecific-ADC combination therapy study in MCL. (Funded by F. Hoffmann-La Roche Ltd; ClinicalTrials.gov, NCT03671018)
- Open Access
- 8 March 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (3) , 154
Analyzing Real-World Infection Risk in Multiple Myeloma Patients Receiving Teclistamab
Background: Teclistamab is an anti-B-cell maturation antigen bispecific antibody used in relapsed, refractory multiple myeloma that induces durable responses but is associated with infectious complications. Real-world data characterizing infection risk remain limited. Methods: We conducted a single-center retrospective cohort study of relapsed/re fractory multiple myeloma patients treated with teclistamab from 1 January 2023 to 20 November 2023. The primary objective was to establish the incidence of infections after initiation of teclistamab. Secondary objectives included infection-related outcomes and identifying potential risk factors for infection. Results: 19 patients received teclistamab with a median age of 72 [IQR: 62–74] years and 73.7% had Karnofsky performance score < 80. A total of 11 (57.9%) patients developed 19 infections, with seven patients having multiple infections. There were five bacteremias, five other bacterial infections, seven respiratory viral infections, and 2 CMV reactivation events. Median time to first infection was 20 days (IQR: 9–87) and median grade of all infections was three (range: 1–5). Of the 19 documented infections, 15 (78.9%) were Grade ≥ 3. A total of 10 patients in the infection group and three in the non-infection group discontinued therapy permanently (p = 0.013). Conclusion: In this real-world cohort, infectious complications emerged early and frequently during teclistamab therapy and were a major driver of treatment interruption and permanent discontinuation. The clinical impact of infection extended beyond acute morbidity, often limiting continued access to an otherwise effective therapy in a heavily pretreated population. These findings highlight the need for proactive, individualized infection risk assessment and for standardized, evidence-informed approaches to infection monitoring, prophylaxis, and treatment modification during teclistamab therapy. Larger, multicenter studies will be essential to define strategies that balance infection risk with treatment durability in patients with limited therapeutic alternatives.
- 8 March 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (3) , 154
Open AccessAnalyzing Real-World Infection Risk in Multiple Myeloma Patients Receiving Teclistamab
Background: Teclistamab is an anti-B-cell maturation antigen bispecific antibody used in relapsed, refractory multiple myeloma that induces durable responses but is associated with infectious complications. Real-world data characterizing infection risk remain limited. Methods: We conducted a single-center retrospective cohort study of relapsed/re fractory multiple myeloma patients treated with teclistamab from 1 January 2023 to 20 November 2023. The primary objective was to establish the incidence of infections after initiation of teclistamab. Secondary objectives included infection-related outcomes and identifying potential risk factors for infection. Results: 19 patients received teclistamab with a median age of 72 [IQR: 62–74] years and 73.7% had Karnofsky performance score < 80. A total of 11 (57.9%) patients developed 19 infections, with seven patients having multiple infections. There were five bacteremias, five other bacterial infections, seven respiratory viral infections, and 2 CMV reactivation events. Median time to first infection was 20 days (IQR: 9–87) and median grade of all infections was three (range: 1–5). Of the 19 documented infections, 15 (78.9%) were Grade ≥ 3. A total of 10 patients in the infection group and three in the non-infection group discontinued therapy permanently (p = 0.013). Conclusion: In this real-world cohort, infectious complications emerged early and frequently during teclistamab therapy and were a major driver of treatment interruption and permanent discontinuation. The clinical impact of infection extended beyond acute morbidity, often limiting continued access to an otherwise effective therapy in a heavily pretreated population. These findings highlight the need for proactive, individualized infection risk assessment and for standardized, evidence-informed approaches to infection monitoring, prophylaxis, and treatment modification during teclistamab therapy. Larger, multicenter studies will be essential to define strategies that balance infection risk with treatment durability in patients with limited therapeutic alternatives.
- Open Access
- 20 February 2026
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 26 (5) , 317-327.e10
Epcoritamab Monotherapy as Outpatient Treatment for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Interim Results From EPCORE NHL-6
- 20 February 2026
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 26 (5) , 317-327.e10
Open AccessEpcoritamab Monotherapy as Outpatient Treatment for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Interim Results From EPCORE NHL-6
- Open Access
- 11 October 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (20) , 5355-5364
High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series
Little is known about the central nervous system (CNS) risk in high-grade B-cell lymphoma, not otherwise specified (HGBL NOS). Hence, we sought to describe the rates of baseline CNS involvement, risk of CNS recurrence after primary therapy, and management strategies in HGBL NOS. In this multicenter retrospective study, we included 160 adults with newly diagnosed HGBL NOS treated between 2016 and 2021 at 20 US institutions. Eleven patients (7%) had baseline CNS involvement at diagnosis (leptomeningeal = 6, parenchymal = 4, and both = 1). Baseline CNS involvement was significantly associated only with MYC rearrangement (OR = 3.5) and testicular (in men) or female pelvic (in women) involvement (OR = 8.1). There was no significant difference in survival outcomes between patients with HGBL NOS with (median PFS = 4 years) or without (median PFS = 2.4 years) baseline CNS involvement (P = 0.45). The cumulative incidence of CNS recurrence at 3 years was 11%. Patients with baseline CNS involvement were at the highest risk (48.5% vs 8% for those without baseline CNS involvement) and were excluded from the risk factors analysis for CNS recurrence. The risk for CNS recurrence was significantly associated with blood or bone marrow involvement, CD5 expression, non–germinal center B-cell subtype, and “dual-expresser lymphoma” phenotype, however, high CNS IPI was not. The prognosis of relapsed HGBL NOS was poor, regardless of whether recurrence was systemic or limited to the CNS, and with currently available salvage strategies, including autologous transplantation and chimeric antigen receptor T-cell modalities, almost all patients with CNS recurrence ultimately succumbed to their disease.
- 11 October 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (20) , 5355-5364
Open AccessHigh-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series
Little is known about the central nervous system (CNS) risk in high-grade B-cell lymphoma, not otherwise specified (HGBL NOS). Hence, we sought to describe the rates of baseline CNS involvement, risk of CNS recurrence after primary therapy, and management strategies in HGBL NOS. In this multicenter retrospective study, we included 160 adults with newly diagnosed HGBL NOS treated between 2016 and 2021 at 20 US institutions. Eleven patients (7%) had baseline CNS involvement at diagnosis (leptomeningeal = 6, parenchymal = 4, and both = 1). Baseline CNS involvement was significantly associated only with MYC rearrangement (OR = 3.5) and testicular (in men) or female pelvic (in women) involvement (OR = 8.1). There was no significant difference in survival outcomes between patients with HGBL NOS with (median PFS = 4 years) or without (median PFS = 2.4 years) baseline CNS involvement (P = 0.45). The cumulative incidence of CNS recurrence at 3 years was 11%. Patients with baseline CNS involvement were at the highest risk (48.5% vs 8% for those without baseline CNS involvement) and were excluded from the risk factors analysis for CNS recurrence. The risk for CNS recurrence was significantly associated with blood or bone marrow involvement, CD5 expression, non–germinal center B-cell subtype, and “dual-expresser lymphoma” phenotype, however, high CNS IPI was not. The prognosis of relapsed HGBL NOS was poor, regardless of whether recurrence was systemic or limited to the CNS, and with currently available salvage strategies, including autologous transplantation and chimeric antigen receptor T-cell modalities, almost all patients with CNS recurrence ultimately succumbed to their disease.
- Open Access
- 2 April 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (7) , 2052
IMPROVE-BMT: A Pilot Randomized Controlled Trial of Prehabilitation Exercise for Adult Hematopoietic Stem Cell Transplant Recipients
Background: There is limited evidence on the effects of aerobic and resistance training exercise interventions to improve physical function and patient-reported outcomes prior to autologous and allogeneic hematopoietic stem cell transplant (HSCT). IMPROVE-BMT was a single-site, pilot randomized controlled trial investigating the feasibility, acceptability, and safety of a pragmatic resistance training exercise program prior to HSCT compared to usual HSCT care. Secondary aims included differences in physical function between the exercise group (EX) and usual care control group (UC). Methods: Outcome measurements were assessed: prior to HSCT, on/around day of HSCT admission, +30 days post-HSCT, and +100 days post-HSCT. The exercise intervention was a home-based exercise program that incorporated resistance-band and bodyweight exercises. Results: Acceptability among participants was 83%; exercise adherence averaged at 92%; and there were zero exercise-related adverse or serious adverse events. The average pre-transplant exercise phase was 6.28 weeks (2.71–18.29 weeks). EX (n = 36) demonstrated larger increases in the six-minute walk test distance, short physical performance battery scores, and 30-s chair stands compared to UC (n = 38) and demonstrated significant within-group improvements for the six-minute walk test, the short physical performance battery, the 30-s chair stands, and the timed up-and-go test. Conclusions: IMPROVE-BMT demonstrates that pragmatic exercise is highly feasible for HSCT recipients and can potentially lead to enhanced recovery that may not be achievable in non-exercisers.
- 2 April 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (7) , 2052
Open AccessIMPROVE-BMT: A Pilot Randomized Controlled Trial of Prehabilitation Exercise for Adult Hematopoietic Stem Cell Transplant Recipients
Background: There is limited evidence on the effects of aerobic and resistance training exercise interventions to improve physical function and patient-reported outcomes prior to autologous and allogeneic hematopoietic stem cell transplant (HSCT). IMPROVE-BMT was a single-site, pilot randomized controlled trial investigating the feasibility, acceptability, and safety of a pragmatic resistance training exercise program prior to HSCT compared to usual HSCT care. Secondary aims included differences in physical function between the exercise group (EX) and usual care control group (UC). Methods: Outcome measurements were assessed: prior to HSCT, on/around day of HSCT admission, +30 days post-HSCT, and +100 days post-HSCT. The exercise intervention was a home-based exercise program that incorporated resistance-band and bodyweight exercises. Results: Acceptability among participants was 83%; exercise adherence averaged at 92%; and there were zero exercise-related adverse or serious adverse events. The average pre-transplant exercise phase was 6.28 weeks (2.71–18.29 weeks). EX (n = 36) demonstrated larger increases in the six-minute walk test distance, short physical performance battery scores, and 30-s chair stands compared to UC (n = 38) and demonstrated significant within-group improvements for the six-minute walk test, the short physical performance battery, the 30-s chair stands, and the timed up-and-go test. Conclusions: IMPROVE-BMT demonstrates that pragmatic exercise is highly feasible for HSCT recipients and can potentially lead to enhanced recovery that may not be achievable in non-exercisers.
- Open Access
- 25 January 2024
- Published by Wiley in Transplant Infectious Disease
- Vol. 26 (2) , e14241
The addition of doxycycline to fluoroquinolones for bacterial prophylaxis in autologous stem cell transplantation for multiple myeloma
Background: Bacterial prophylaxis with a fluoroquinolone (FQ) during autologous stem cell transplant (ASCT) is common, although not standardized among transplant centers. The addition of doxycycline (doxy) to FQ prophylaxis was previously linked to reduced neutropenic fever and bacteremia in multiple myeloma (MM) patients undergoing ASCT although several confounders were present. We compared the incidence of neutropenic fever and bacteremia between MM patients variably receiving prophylaxis with FQ alone and FQ‐doxy during ASCT.Methods: Systematic retrospective chart review of MM patients who underwent ASCT between January 2016 and December 2021. The primary objective was to determine the effect of bacterial prophylaxis on neutropenic fever and bacteremia within 30 days of ASCT. Multivariable logistic regression for neutropenic fever and univariate logistic regression for bacteremia accounted for differences in subject characteristics between groups.Results: Among 341 subjects, 121 received FQ and 220 received FQ‐doxy for prophylaxis. Neutropenic fever developed in 67 (55.4%) and 87 (39.5%) subjects in the FQ and FQ‐doxy groups, respectively (p = .005). Bacteremia was infrequent, with 5 (4.1%) and 5 (2.3%) cases developing in the FQ and FQ‐doxy groups, respectively (p = .337). Among Gram‐negative bacteremia events, 7/7 Escherichia coli strains were FQ‐resistant, and 5/7 were ceftriaxone‐resistant.Conclusion: The FQ‐doxy prophylaxis group had fewer cases of neutropenic fever than the FQ group, however, there was no significant difference in bacteremia. High rates of antibiotic resistance were observed. An updated randomized controlled trial investigating appropriate prophylaxis for ASCT in the context of current oncology standards and changing antimicrobial resistance rates is warranted. image
- 25 January 2024
- Published by Wiley in Transplant Infectious Disease
- Vol. 26 (2) , e14241
Open AccessThe addition of doxycycline to fluoroquinolones for bacterial prophylaxis in autologous stem cell transplantation for multiple myeloma
Background: Bacterial prophylaxis with a fluoroquinolone (FQ) during autologous stem cell transplant (ASCT) is common, although not standardized among transplant centers. The addition of doxycycline (doxy) to FQ prophylaxis was previously linked to reduced neutropenic fever and bacteremia in multiple myeloma (MM) patients undergoing ASCT although several confounders were present. We compared the incidence of neutropenic fever and bacteremia between MM patients variably receiving prophylaxis with FQ alone and FQ‐doxy during ASCT.Methods: Systematic retrospective chart review of MM patients who underwent ASCT between January 2016 and December 2021. The primary objective was to determine the effect of bacterial prophylaxis on neutropenic fever and bacteremia within 30 days of ASCT. Multivariable logistic regression for neutropenic fever and univariate logistic regression for bacteremia accounted for differences in subject characteristics between groups.Results: Among 341 subjects, 121 received FQ and 220 received FQ‐doxy for prophylaxis. Neutropenic fever developed in 67 (55.4%) and 87 (39.5%) subjects in the FQ and FQ‐doxy groups, respectively (p = .005). Bacteremia was infrequent, with 5 (4.1%) and 5 (2.3%) cases developing in the FQ and FQ‐doxy groups, respectively (p = .337). Among Gram‐negative bacteremia events, 7/7 Escherichia coli strains were FQ‐resistant, and 5/7 were ceftriaxone‐resistant.Conclusion: The FQ‐doxy prophylaxis group had fewer cases of neutropenic fever than the FQ group, however, there was no significant difference in bacteremia. High rates of antibiotic resistance were observed. An updated randomized controlled trial investigating appropriate prophylaxis for ASCT in the context of current oncology standards and changing antimicrobial resistance rates is warranted. image
- Open Access
- 12 January 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (2) , 957
Clofarabine Preconditioning followed by Allogeneic Transplant Using TBI and Post-Transplant Cyclophosphamide for Relapsed Refractory Leukemia
Acute myeloid leukemia patients with induction failure or relapsed refractory disease have minimal chance of achieving remission with subsequent treatments. Several trials have shown the feasibility of clofarabine-based conditioning in allogeneic stem cell transplants (allo-HSCT) for non-remission AML patients. Pre-transplant conditioning with clofarabine followed by reduced-intensity allo-HSCT has also demonstrated a potential benefit in those patients with human leukocyte antigen (HLA)-identical donors, but it is not commonly used in haploidentical and mismatched transplants. In this case report, we describe our experience of seven cases of non-remission AML who received clofarabine preconditioning followed by an allo-HSCT with PTCy. The 2-year overall survival and disease-free survival was 83.3% (95% confidence interval (CI): 27.3–97.9%) and 85.7% (95% CI: 33.4–97.9%). Median days of neutrophil and platelet recovery were 16 (range of 13–23) and 28 (range of 17–75), respectively. The cumulative incidence of grade II-IV acute graft-versus-host disease (GVHD) at day 100 and chronic GVHD at 1-year showed 28.6% (95% CI: 8–74.2%) and 28.6% (95% CI: 3–63.9%), respectively. The two-year relapse rate was 14.3% (95% CI: 2.14–66.6%). One-year GVHD-free relapse-free survival (GFRS) at 1-year was 71.4% (95% CI: 25.8–92%). Our patients showed successful outcomes with clofarabine preconditioning to reduce the leukemic burden at the pre-transplant period followed by PTCy to reduce GVHD resulting in lower relapsed rate and better GFRS in these patients.
- 12 January 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (2) , 957
Open AccessClofarabine Preconditioning followed by Allogeneic Transplant Using TBI and Post-Transplant Cyclophosphamide for Relapsed Refractory Leukemia
Acute myeloid leukemia patients with induction failure or relapsed refractory disease have minimal chance of achieving remission with subsequent treatments. Several trials have shown the feasibility of clofarabine-based conditioning in allogeneic stem cell transplants (allo-HSCT) for non-remission AML patients. Pre-transplant conditioning with clofarabine followed by reduced-intensity allo-HSCT has also demonstrated a potential benefit in those patients with human leukocyte antigen (HLA)-identical donors, but it is not commonly used in haploidentical and mismatched transplants. In this case report, we describe our experience of seven cases of non-remission AML who received clofarabine preconditioning followed by an allo-HSCT with PTCy. The 2-year overall survival and disease-free survival was 83.3% (95% confidence interval (CI): 27.3–97.9%) and 85.7% (95% CI: 33.4–97.9%). Median days of neutrophil and platelet recovery were 16 (range of 13–23) and 28 (range of 17–75), respectively. The cumulative incidence of grade II-IV acute graft-versus-host disease (GVHD) at day 100 and chronic GVHD at 1-year showed 28.6% (95% CI: 8–74.2%) and 28.6% (95% CI: 3–63.9%), respectively. The two-year relapse rate was 14.3% (95% CI: 2.14–66.6%). One-year GVHD-free relapse-free survival (GFRS) at 1-year was 71.4% (95% CI: 25.8–92%). Our patients showed successful outcomes with clofarabine preconditioning to reduce the leukemic burden at the pre-transplant period followed by PTCy to reduce GVHD resulting in lower relapsed rate and better GFRS in these patients.
- Open Access
- 25 October 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (21) , 6381-6394
High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study
In this multi-institutional retrospective study, we examined the characteristics and outcomes of 160 patients with high-grade B-cell lymphoma, not otherwise specified (HGBL-NOS)—a rare category defined by high-grade morphologic features and lack of MYC rearrangements with BCL2 and/or BCL6 rearrangements ("double hit"). Our results show that HGBL-NOS tumors are heterogeneous: 83% of patients had a germinal center B-cell immunophenotype, 37% a dual-expressor immunophenotype (MYC and BCL2 expression), 28% MYC rearrangement, 13% BCL2 rearrangement, and 11% BCL6 rearrangement. Most patients presented with stage IV disease, a high serum lactate dehydrogenase, and other high-risk clinical factors. Most frequent first-line regimens included dose-adjusted cyclophosphamide, doxorubicin, vincristine, and etoposide, with rituximab and prednisone (DA-EPOCH-R; 43%); rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP; 33%); or other intensive chemotherapy programs. We found no significant differences in the rates of complete response (CR), progression-free survival (PFS), or overall survival (OS) between these chemotherapy regimens. CR was attained by 69% of patients. PFS at 2 years was 55.2% and OS was 68.1%. In a multivariable model, the main prognostic factors for PFS and OS were poor performance status, lactate dehydrogenase >3 × upper limit of normal, and a dual-expressor immunophenotype. Age >60 years or presence of MYC rearrangement were not prognostic, but patients with TP53 alterations had a dismal PFS. Presence of MYC rearrangement was not predictive of better PFS in patients treated with DA-EPOCH-R vs R-CHOP. Improvements in the diagnostic criteria and therapeutic approaches beyond dose-intense chemotherapy are needed to overcome the unfavorable prognosis of patients with HGBL-NOS.
- 25 October 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (21) , 6381-6394
Open AccessHigh-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study
In this multi-institutional retrospective study, we examined the characteristics and outcomes of 160 patients with high-grade B-cell lymphoma, not otherwise specified (HGBL-NOS)—a rare category defined by high-grade morphologic features and lack of MYC rearrangements with BCL2 and/or BCL6 rearrangements ("double hit"). Our results show that HGBL-NOS tumors are heterogeneous: 83% of patients had a germinal center B-cell immunophenotype, 37% a dual-expressor immunophenotype (MYC and BCL2 expression), 28% MYC rearrangement, 13% BCL2 rearrangement, and 11% BCL6 rearrangement. Most patients presented with stage IV disease, a high serum lactate dehydrogenase, and other high-risk clinical factors. Most frequent first-line regimens included dose-adjusted cyclophosphamide, doxorubicin, vincristine, and etoposide, with rituximab and prednisone (DA-EPOCH-R; 43%); rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP; 33%); or other intensive chemotherapy programs. We found no significant differences in the rates of complete response (CR), progression-free survival (PFS), or overall survival (OS) between these chemotherapy regimens. CR was attained by 69% of patients. PFS at 2 years was 55.2% and OS was 68.1%. In a multivariable model, the main prognostic factors for PFS and OS were poor performance status, lactate dehydrogenase >3 × upper limit of normal, and a dual-expressor immunophenotype. Age >60 years or presence of MYC rearrangement were not prognostic, but patients with TP53 alterations had a dismal PFS. Presence of MYC rearrangement was not predictive of better PFS in patients treated with DA-EPOCH-R vs R-CHOP. Improvements in the diagnostic criteria and therapeutic approaches beyond dose-intense chemotherapy are needed to overcome the unfavorable prognosis of patients with HGBL-NOS.